UCB backs epilepsy-focused digital heath startup Nile AIBelgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing Share XUCB backs epilepsy-focused digital heath startup Nile AIhttps://pharmaphorum.com/news/ucb-backs-epilepsy-focused-digital-heath-startup-nile-ai/
Israel’s NeuroHelp to trial AI device that predicts epileptic seizuresNeuroHelp, a spin-off from Israel’s Ben-Gurion University of the Negev, has developed what it claims to be the Share XIsrael’s NeuroHelp to trial AI device that predicts epileptic seizureshttps://pharmaphorum.com/news/israels-neurohelp-to-trial-ai-device-that-predicts-epileptic-seizures/
Searching for answers in rare epilepsyGeneticist Dr Charles Steward has spent his career studying the human genome – but his work became much Share XSearching for answers in rare epilepsyhttps://pharmaphorum.com/views-analysis-patients/searching-for-answers-in-rare-epilepsy/
Sanofi faces possible manslaughter charges in epilepsy drug probeSanofi has been placed under formal investigation in France for possible charges including manslaughter relating to the epilepsy Share XSanofi faces possible manslaughter charges in epilepsy drug probehttps://pharmaphorum.com/news/sanofi-faces-possible-manslaughter-charges-in-epilepsy-drug-probe/
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubtShares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had Share XFailed trial puts future of UCB’s epilepsy drug padsevonil in doubthttps://pharmaphorum.com/news/failed-trial-puts-future-of-ucbs-epilepsy-drug-padsevonil-in-doubt/
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drugSwiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop Share XNeurocrine signs $400M-plus deal with Idorsia for epilepsy drughttps://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
GW Pharma’s cannabis-derived epilepsy drug approved in EUGW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The Share XGW Pharma’s cannabis-derived epilepsy drug approved in EUhttps://pharmaphorum.com/news/gw-pharmas-cannabis-derived-epilepsy-drug-approved-in-eu/
GW confident epilepsy drug will get NHS funding despite NICE rejectionThe UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis Share XGW confident epilepsy drug will get NHS funding despite NICE rejectionhttps://pharmaphorum.com/news/no-repeat-of/
